EP2309982A2 - Formulation copolymérique à libération contrôlée présentant une cinétique de libération améliorée - Google Patents

Formulation copolymérique à libération contrôlée présentant une cinétique de libération améliorée

Info

Publication number
EP2309982A2
EP2309982A2 EP09758744A EP09758744A EP2309982A2 EP 2309982 A2 EP2309982 A2 EP 2309982A2 EP 09758744 A EP09758744 A EP 09758744A EP 09758744 A EP09758744 A EP 09758744A EP 2309982 A2 EP2309982 A2 EP 2309982A2
Authority
EP
European Patent Office
Prior art keywords
copolymer
plg
release
oligomer
bioactive agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09758744A
Other languages
German (de)
English (en)
Inventor
Richard L. Norton
Eric Dadey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tolmar Therapeutics Inc
Original Assignee
Tolmar Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tolmar Therapeutics Inc filed Critical Tolmar Therapeutics Inc
Publication of EP2309982A2 publication Critical patent/EP2309982A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Definitions

  • Copolymer compositions adapted for use in controlled release delivery systems such as biodegradable and bioerodible implants are known.
  • Polyesters such as poly(DL-lactide-glycolide) (“PLG”) copolymers can be used, as the ester linkages are readily degraded in body tissues by endogenous esterases as well as by uncatalyzed hydrolytic cleavage yielding non-toxic, water-soluble hydrolysis products, and controlled release systems incorporating PLG copolymers have been widely described. See, for example, U.S. Patent Nos.
  • Polyesters including poly-lactide, poly-glycolide, and copolymers thereof can be prepared from glycolide (l ,4-dioxan-2,5-dione, glycolic acid cyclic dimer lactone) and lactide (3,6-dimethyl-l ,4-dioxan-2,5-dione, lactic acid cyclic dimer lactone), or from glycolate (2-hydroxyacetate) and lactate (2- hydroxypropionate).
  • copolymer materials are particularly favored for this application due to their facile breakdown in vivo by body fluids or enzymes in the body to non-toxic materials, and their favorable properties in temporally controlling the release of medicaments and biologically active agents ("bioactive agents") that may be contained within a mass of the controlled release formulation incorporating the polymer that has been implanted within a patient's body tissues.
  • bioactive agents biologically active agents
  • controlled release systems are adapted to provide for as constant a rate of release as possible of the bioactive agent over the time period that the implant persists within the body.
  • Flowable delivery systems such as the Atrigel ® systems, are disclosed in U.S. Patent Numbers 6,565,874, 6,528,080, 6,461 ,631 , 6,395,293, and references found therein.
  • Flowable delivery systems like the Atrigel R system include a biodegradable polymer such as a PLG copolymer, a bioactive agent, and an organic solvent that has at least a very slight solubility in body fluids.
  • the substantially liquid (“flowable") solution of the delivery system is injected into a patient's tissues, typically as a single bolus, the organic solvent diffuses into surrounding body fluids, causing precipitation or gelation of the water-insoluble polymer containing the bioactive agent.
  • a skin forms on the deposited liquid mass, bringing about formation of the semi-solid deposit known as a depot that contains the remaining solution of the polymer and the bioactive agent in the solvent.
  • the solvent continues to diffuse out and body fluids to diffuse in, bringing about ongoing precipitation of the polymer with the bioactive agent, until a gelled or solid mass remains. Channels or pores may form in the depot as part of this process.
  • Due to the biodegradable nature of the polymer in the presence of body fluids and of enzymes within the body the polymer slowly degrades into soluble non-toxic hydrolysis products, releasing the contained bioactive agent over a period of time. This process continues until the depot is substantially completely dissolved and all the bioactive agent is released. It is understood that such depots can be adapted to persist for various lengths of time within the body, such as about 30 days, about 60 days, or about 3 months, 4 months, or 6 months.
  • a relatively constant level of the bioactive agent can be maintained within the patient's body for the period of time over which the formulation is adapted to release the agent. It is generally undesirable to have fluctuations in the rate of release, and thus in the levels within the patient's body, of the bioactive agent following as well as during the initial period following administration of the formulation to the patient. For example, it is undesirable to have an increasing rate of release or a decreasing rate of release, or to have the rate of release peak at some time point and then decline, during the entire time period for which the formulation is adapted to release the bioactive agent.
  • the most desirable rate of release is typically a constant, or zero-order, rate of release, wherein the amount of the bioactive agent released per time interval is constant, up until the point of complete dissolution of the controlled release implant in the patient's body.
  • rate of release typically a constant, or zero-order, rate of release, wherein the amount of the bioactive agent released per time interval is constant, up until the point of complete dissolution of the controlled release implant in the patient's body.
  • At least two problems involving a less than optimal rate of release have been found using art PLG copolymers in controlled release systems: an initial burst effect, and a degree of variability in the subsequent rate of release over the lifetime of the depot in the body. It has been found that the release of many bioactive agents such as peptides, proteins, and small molecule drugs from controlled release systems can occur at a higher than optimal rate during the first 24 hours after implantation under certain conditions.
  • the second effect involves a variable, non-linear rate of release of the bioactive agent as the implanted formulation undergoes its period of degradation in the body that deviates from linearity or zero-order kinetics. This effect can occur when using purified copolymer formulations adapted to reduce or minimize the initial burst effect as well as when using unpurified copolymers.
  • constant release copolymer formulations as defined herein when used in a flowable delivery system such as an Atrigel" system, provide for substantially more constant rates of release of bioactive agents over the period of time that the depot persists within the body tissues of a patient.
  • This relatively constant rate of release results in an improved release profile compared to other copolymer formulations, because it tends to maintain a more constant level of the bioactive agent with the body tissues, which is generally desirable from a medical perspective.
  • controlled release formulations involving various embodiments of the inventive constant release copolymer have unexpectedly been found to reduce variations in the rate of release of the bioactive agent, especially later in the process of dissolution of the implanted depot, resulting in a release profile closer to a "zero-order", i.e., linear, rate of release.
  • constant release copolymer formulations of the present invention including of a mixture of a PLG copolymer and a PLG oligomer (referred to hereinafter as a "constant release copolymer composition"), when incorporated into a controlled release formulation for a bioactive agent, provides for a substantially constant rate of release of the bioactive agent from a depot over substantially the entire period of time that the depot persists in the patient's body tissues.
  • the PLG copolymer used in the inventive constant release copolymer composition can be one of the well-known PLG copolymers as described in U.S. Patent Numbers 6,565,874, 6,528,080, 6,461,631, 6,395,293, and elsewhere.
  • the PLG copolymer can be a purified PLG copolymer that can be of the type that when incorporated into a controlled release formulation of the Atrigel ® type provides for a reduced initial burst effect (referred to hereinafter as a "low burst copolymer").
  • a "low burst, constant release copolymer composition” is obtained.
  • the low burst PLG copolymer can be a solvent precipitation-purified PLG copolymer such as is described in patent application U.S. Ser. No. 60/901,435, filed Feb.
  • the low burst PLG copolymer can be a copolymer incorporating a "core diol" unit, such as the copolymer obtained when hexane- 1 ,6-diol is used as an initiator for polymerization of lactide and glycolide, producing a PLG copolymer with substantially no free carboxylic acid end groups, as is described in patent application U.S. Ser. No. 1 1/469,392, filed Aug. 31, 2006, by the inventors herein.
  • the low burst PLG copolymer can be can be a PLG copolymer purified by a supercritical fluid extraction (SFE) process, as described in PCT/US2007/021749, filed Oct. 1 1, 2007, by the inventors herein, wherein the SFE-purified PLG copolymer can have a relatively narrow distribution of individual polymer molecular weights, a limited content of monomers, undesirable short-chain PLG copolymers, and copolymer molecules with excessively high individual molecular weights.
  • SFE supercritical fluid extraction
  • a constant release copolymer composition is obtained that unexpectedly provides for a greater linearity of release of a bioactive substance over time after implantation in body tissues when the constant release copolymer composition, the bioactive substance, and an organic solvent that is at least somewhat soluble in body fluids are combined in an Atrigel ® type controlled release formulation and implanted into the living tissue of a mammal.
  • the PLG oligomer can be an oligomer comprising lactide or glycolide units, or both, wherein the average molecular weight of the oligomer is less than about 10 kDa, preferably about 7-8 kDa.
  • the PLG oligomer can be a pure poly(lactide), termed a "PLA", wherein the lactide content is 100%.
  • the PLG oligomer can be a "65/35-PLG", wherein the lactide content is 65% and the glycolide content is 35%.
  • the PLG oligomer can be substantially free of terminal carboxylic acid groups, for example having any such carboxylic acids capped as esters such as methyl esters.
  • the PLG oligomer can also be substantially free of any carboxylic acid groups distributed on the molecular chain.
  • inventive constant release copolymer composition when incorporated into a flowable delivery formulation, reduces or minimizes variations in the rate of release of the bioactive agent over the period of time that the depot persists within the patient's body tissue, compared to a flowable delivery system containing an art copolymer. This control persists until biodegradation of the depot is complete.
  • use of the inventive constant release copolymer composition avoids a decrease or an increase in the rate of release of the agent as the depot nears the end of its time of residence in the body, that is, immediately prior to final dissolution of the depot.
  • Another advantage is realized when an embodiment of a low burst, constant release copolymer composition of the invention is incorporated into a controlled release formulation of the Atrigel ® type.
  • the initial burst effect is minimized and the rate of release of the bioactive agent over the lifetime of the depot within the patient's body is kept at a more constant level than is observed with art delivery systems, thus overcoming two of the major disadvantages of controlled delivery systems presently in use.
  • An embodiment of the present invention provides a constant release copolymer composition that includes a mixture of a PLG copolymer and a PLG oligomer of less than about 10 kDa.
  • the oligomer can be substantially lacking in carboxylic end groups.
  • the inventive constant release copolymer composition is adapted for use in a controlled release formulation for release of a bioactive agent from a depot within a patient's body tissues, the formulation providing a substantially constant rate of release of the agent over a period of time that the depot persists within the body tissues.
  • the relatively constant rate of release of the bioactive substance by the depot results in a relatively constant level of the bioactive substance in the patient's body, which is generally desirable from a medical perspective.
  • Various embodiments of the present invention further provide methods of preparing the inventive formulation, involving combining a PLG oligomer and a PLG copolymer, a bioactive agent, and an organic solvent having at least a very slight solubility in body fluids.
  • Various embodiments of the present invention further provide methods of administering a bioactive agent to a patient over a prolonged period of time, wherein a substantially constant rate of release of the bioactive agent is achieved, comprising administering to the patient a controlled release formulation comprising the inventive copolymer formulation, the bioactive agent, and an organic solvent having at least a very slight solubility in body fluids.
  • Various embodiments of the present invention further provide the use of the controlled release formulation described herein in the manufacture of a medicament for administering a bioactive agent to a patient over a prolonged period of time, wherein a substantially constant rate of release of the bioactive agent is achieved.
  • the formulation is administered as a depot.
  • the depot is emplaced subcutaneously.
  • the patient suffers from a malcondition and the bioactive agent is adapted to treat, arrest, or palliate the malcondition.
  • the malcondition is prostate cancer and the agent is leuprolide.
  • the malcondition is acromegaly and the agent is octreotide.
  • the malcondition is psychosis and the agent is risperidone.
  • the malcondition is pain and the agent is an analgesic or an anti-inflammatory.
  • Figure 1 the release profiles of risperidone from depots formed using a flowable delivery system in rats are shown.
  • the system is adapted to release risperidone over a period of about 28 days, and a zero-order, constant release rate would exhibit the ideal straight line as shown, with about 90% of the agent being released over the 28 day period.
  • the control formulation including 15% risperidone in copolymer PLGH(p) (a purified 80/20 PLGH, i.e., 80 mole% lactide, 20 mole % glycolide, and free carboxylic acid end groups) without any added PLG oligomer, in N-methylpyrrolidone (NMP) solution, release profile is indicated by closed circles.
  • the closed diamonds indicates the release from an equivalent formulation but with unpurified 80/20 PLGH.
  • the other symbols indicate the release from inventive constant release copolymer formulations.
  • Figure 2 has the Day One release data from the same study as described for Figure 1 above.
  • Figure 3 shows data for the release of octreotide over a period of 90 days.
  • the control formulation uses purified PLGH copolymer, in this case 85/15 PLGH(p), without any added PLG oligomer.
  • inventive formulations containing oligomers as additives are represented by the other symbols.
  • Figure 4 shows a 90-day release profile of octreotide in rats from a control and two inventive copolymer compositions, comparable to the study shown in Figure 3, except using an unpurified PLGH copolymer.
  • Figure 5 shows Day One release data for GHRP-I from depots of controlled release formulations emplaced in rats.
  • Figure 6 shows 28-day release profiles for GHRP-I from controlled release depots emplaced in rats for the same set of formulations as in Figure 5.
  • the control formulation (closed circles) uses purified PLGH copolymer, in this case 75/25 PLGH(p), without any added PLG oligomer.
  • the inventive formulations containing oligomers as additives are represented by the other symbols.
  • Figure 7 shows Day One release data for GHRP-I from depots of controlled release formulations emplaced in rats.
  • the formulations include a control containing only an unpurified 75/25 PLGH and six inventive formulations, each containing a copolymer system of the unpurified 75/25 PLGH and a PLG oligomer, such as a PLA oligomer, 65/35 PLG oligomer or 65/35 PLGH oligomer.
  • Figure 8 shows 28-day release profiles for GHRP-I from controlled release depots emplaced in rats for the same set of formulations as in Figure 7.
  • the control formulation (closed circles) uses unpurified PLGH copolymer without any added PLG oligomer.
  • the inventive formulations containing oligomers as additives are represented by the other symbols.
  • a "copolymer” or a “PLG copolymer” as the terms are used herein refer to a poly(lactide-glycolide) polymer formed of lactide (or lactate) and glycolide (or glycolate) units in a defined molar proportion.
  • the molar proportion can range from 100 mole% lactide to 100 mole% glycolide but typically ranges from about 50-100 mole% lactide.
  • a pure poly(lactide), i.e., 100 mole% lactide, also known as PLA is a PLG copolymer within the meaning herein.
  • Copolymers composed of both lactide and glycolide units can be described in terms of their molar compositions; i.e., a 65/35 PLG is understood to consist of 65 mole% lactide units and 35 mole% glycolide units.
  • a copolymer can include neutral poly(lactide-glycolide) molecular chains that terminate in alcohol or ester groups, or ionic poly(lactide-glycolide) molecular chains that terminate in carboxylic acid groups (also referred to as PLGH copolymers).
  • PLG copolymers include compositions referred to in the art as poly(lactate-glycolate), poly(lactate(co)glycolate), poly(lactide-glycolide), poly(lactide(co)glycolide), and the like, with the understanding that additional moieties may be included, such as core or initiator groups (for example, diols, hydroxyacids, and the like), capping groups (for example, esters of terminal carboxyl groups, and the like) and other pendant groups or chain extension groups covalently linked to or within the polyester backbone, including groups that cross-link the substantially linear polyester molecular chains.
  • core or initiator groups for example, diols, hydroxyacids, and the like
  • capping groups for example, esters of terminal carboxyl groups, and the like
  • other pendant groups or chain extension groups covalently linked to or within the polyester backbone, including groups that cross-link the substantially linear polyester molecular chains.
  • a “formulation” as the term is used herein is a composition including the inventive constant release copolymer composition plus a bioactive agent in a form adapted for administration to a patient for controlled release of the bioactive agent into the patient's body tissues.
  • a neutral PLG can be synthesized by catalyzed polymerization of lactide and glycolide reagents (cyclic dimers) from a core diol, such as hexane-1 ,6-diol, wherein ester bonds are formed between the end of the growing chains and the newly added lactide/glycolide units resulting in polymer chains wherein both ends have terminal hydroxyl groups, which are neutral, as is described in patent application U.S. Ser. No. 11/469,392 by the inventors herein.
  • an ionic or acidic PLG (a PLGH) can be prepared by polymerization of lactide/glycolide reagents initiated by lactic acid, wherein one end of the PLG chain that is formed bears an ionizable carboxylic acid group.
  • An acidic PLGH can be capped with an alcohol, that is, an ester group can be formed from the free carboxylic end group and the alcohol, to provide a neutral PLG copolymer within the meaning herein.
  • burst effect or “initial burst effect” are used herein to refer to the situation in which a higher than average rate of diffusion of a bioactive agent out of a controlled release formulation occurs immediately following emplacement of a liquid delivery system, for example, within 1-2 days following emplacement.
  • higher than average is meant that during this initial time period following emplacement of the controlled release formulation with body tissues, the rate of release of the agent is higher than is seen on the average over the entire period of time that the implant continues to release the agent within the body tissues.
  • a burst effect represents a surge of the bioactive agent, which can amount to 25-30% of the total agent contained in the depot, immediately after emplacement that tapers off to the lower rate of release that occurs throughout the total time period that the depot persists within the body tissues.
  • a "low burst copolymer” is a copolymer that, when incorporated into a controlled release formulation, for example of the Atrigel type, provides for a low initial burst effect and avoids the undesired effects on the patient of a transient high level of the bioactive agent immediately following emplacement of the depot.
  • oligomer or a “PLG oligomer” as the terms are used herein refers to a PLG copolymer as the term is defined above wherein the average molecular weight is about 5-10 kDa, preferably about 7-8 kDa.
  • a "hydrophobic" PLG oligomer is an oligomer wherein the mole% of lactide units is greater than about 50%, i.e., the oligomer includes more lactide units than glycolide units. The proportion of lactide units can be equal to or greater than 65 mole%, up to and including 100 mole%. Lactide units, incorporating a side chain methyl group, are known to be more hydrophobic than are glycolide units, which lack the methyl group.
  • a PLG oligomer that substantially lacks "free carboxylic acid groups” is a neutral PLG copolymer within the meaning herein, including only non-ionizable end groups such as hydroxyl groups or ester groups ("capped") and also lacking any pendant free carboxylic acid groups.
  • a "substantially constant rate of release” as used herein means that the release per unit time ("rate of release") of the bioactive agent from a depot of a controlled release formulation into the body of a patient is relatively constant over the period of time during which the formulation is adapted to release the agent.
  • a "substantially constant” rate of release means that every unit of time during that period, such as every day during that period, the amount of bioactive agent released into the patient's body is approximately a constant amount.
  • a “liquid delivery system” or a “flowable delivery system” is a combination of polymer, bioactive agent and organic solvent, such as in the Atrigel system.
  • the solvent which is at least slightly soluble in body fluids, disperses into the tissue and body fluid diffuses into the injected bolus, thereby causing coagulation of the polymer into a solid or semi-solid mass, which then undergoes biodegradation over time, releasing the bioactive agent.
  • the organic solvent has at least a very slight solubility in body fluids, and can be completely soluble in body fluids, such that it can diffuse into the body fluids and vice versa.
  • Solvents that can be used with the inventive polymers for a liquid or flowable delivery system include N- methylpyrrolidone, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, polyethylene glycol 200, polyethylene glycol 300, or methoxypolyethyleneglycol 350.
  • the "molecular weight” or the “average molecular weight” of a copolymer or an oligomer is referred to, it is a weight average molecular weight, as is well known in the art. If the average molecular weight being referred to is the number-average molecular weight, it will be explicitly stated in this specification.
  • the average molecular weight being referred to is the number-average molecular weight, it will be explicitly stated in this specification.
  • the individual molecular weights of the component individual molecules (molecular chains) are referred to, the term “individual molecular weight” is used herein or it will be clear that the molecular weight of a single polymer molecule is being referred to. Weight average molecular weights are determined by the use of gej permeation chromatography (GPC) with reference to polystyrene standards, as is well known in the art.
  • GPC gej permeation chromatography
  • polydispersity index is defined as the weight- average molecular weight of a sample of a polymer material divided by the number-average molecular weight of the sample of the polymer material.
  • the polydispersity index is well-known to relate to the distribution of molecular weights in a polymer. The higher the value of the polydispersity index, the broader the spread of individual molecular weights of the polymer molecular chains making up the polymer material. The lower the value of the polydispersity index, the more uniform and tightly grouped are the individual molecular weights of the individual polymer molecules making up the polymer material in question.
  • lactate and glycocolate refer to either the hydroxyacids, lactic acid and glycolic acid respectively or their salts (lactates and glycolates) which can be used as reagents in preparation of PLG copolymers, or refer to those moieties as residues incorporated via ester bonds into the PLG copolymer polyester molecular chains.
  • lactate lactate
  • glycolic acid glycolic acid
  • a statement about polymerization of lactide and glycolide refers to a polymerization reaction of the cyclic dimeric esters
  • a statement about a lactide or glycolide residue within a copolymer molecular chain refers to that grouping of atoms, ring-opened, and incorporated into the copolymer chain.
  • each incorporated lactide or glycolide residue includes a pair of lactate or glycolate monomeric units, respectively.
  • lactide and glycolide residue in a copolymer molecular chain mean double (dimeric) units of two lactate (L-L), or two glycolate (G-G), residues in the molecular chain, respectively, such as is believed to result from the polymerization of lactide and glycolide.
  • the terms mean single lactate (L) or glycolate (G) residues in the molecular chain, respectively, which can be within a lactide (L-L) or a glycolide (G-G) residue if the given lactate or glycolate is adjacent to another lactate or glycolate residue, respectively, regardless of the method used to prepare the copolymer molecular chain.
  • this arrangement of residues is not all or none. Instead, the arrangement is a predominance.
  • L-L and G-G residues will be present with some L and G (single) residues also present.
  • the chemical reason underlying this characterization is the polymerization process. During polymerization, growing polymer chains are broken and reformed. This scission may split dimer residues and recombine single residues.
  • L and G (single) residues will be present on a statistical basis. This kind of polymer will have a relatively few sequences including repeats of dimer residues because of entropy factors.
  • lactic acid includes D-lactic acid, L-lactic acid, DL- lactic acid, or any combination thereof
  • lactate includes DD-lactide, DL- lactide, LD-lactide, LL-lactide, or any combination thereof.
  • a substantially linear molecular chain that is formed by a polymerization process such as a copolymer molecule that is within a copolymer material of the invention, has two ends, each end with a nearby "end domain,” and an "internal domain" between the end domains.
  • the terms are not exact, but rather describe general regions of a copolymer molecular chain, each end domain being the approximately 10-20% of the total length of the chain terminating at each of the two chain ends, and the internal domain being the remaining approximately 60- 80% of the chain that lies between the end domains.
  • a “solvent” is an organic liquid that serves to dissolve a copolymer material to provide a homogeneous solution.
  • non-solvent refers to a precipitation solvent, a usually organic liquid, that is not a solvent for the copolymer. It is in this context that the term “non-solvent” is used herein.
  • Two liquids, such as a solvent and a non-solvent are “miscible” when they combine with each other in all proportions without phase separation. Solvents may be "soluble” in each other but not “miscible” when they can combine without phase separation in some, but not in all, relative proportions.
  • a solvent is "at least very slightly soluble in body fluids" when a measurable or significant quantity of the solvent is found to dissolve in aqueous liquid compositions with the properties of human body fluids.
  • the organic solvent is of sufficient solubility in body fluids to diffuse from an injected bolus into body fluids such that the contained copolymers can precipitate and form a skin surrounding the bolus to provide the solid or semi-solid depot.
  • the present invention is directed to a controlled release copolymer formulation including a constant release copolymer composition, which includes a mixture of a PLG copolymer and PLG oligomer, methods of making the copolymer composition, and methods of using the copolymer composition.
  • a constant release copolymer composition which includes a mixture of a PLG copolymer and PLG oligomer, methods of making the copolymer composition, and methods of using the copolymer composition.
  • Embodiments of the inventive constant release copolymer composition are adapted for use in controlled release formulations for release of a bioactive agent from a depot within a patient's body tissues, the formulation providing a substantially constant rate of release of the agent over a period of time that the depot persists within the body tissues.
  • controlled release formulations such as Atrigel type flowable compositions, incorporating PLG copolymers, and also including purified PLG low-burst copolymers such as PLG(p) copolymers, can exhibit less than optimal non-linear kinetics of release of the bioactive agent after the initial burst period, especially late in the depot's lifetime. It has surprisingly been found that addition of a defined amount of a PLG oligomer to the PLG copolymer, the composition then being incorporated into a flowable delivery system that is emplaced within body tissues to form a depot, can result in improved linearity of release of the bioactive agent. As a result, the release profile of the agent over time more closely approximates a zero-order kinetics model.
  • the PLG oligomer can be a relatively hydrophobic oligomer, with the lactate content ranging from about 60% to about 100%.
  • the PLG oligomer can be substantially lacking free carboxylic acid groups, either terminal or pendant. It is additionally surprising that this addition of oligomer, particularly substitution of oligomer for a portion of base polymer, can be done without increasing the burst effect.
  • PLG(p) copolymer One type of low burst PLG copolymer, referred to herein as a "PLG(p) copolymer,” is a PLG copolymer adapted for use in a controlled release formulation characterized by a weight average molecular weight of about 10 kilodaltons to about 50 kilodaltons and a polydispersity index of about 1.4-2.0, and having separated therefrom a copolymer fraction characterized by a weight average molecular weight of about 4 kDa to about 10 kDa and a polydispersity index of about 1.4 to 2.5.
  • PLG(p) copolymer a PLG copolymer adapted for use in a controlled release formulation characterized by a weight average molecular weight of about 10 kilodaltons to about 50 kilodaltons and a polydispersity index of about 1.4-2.0, and having separated therefrom a copolymer fraction characterized by a weight average mo
  • this PLG low-burst copolymer material can be prepared by dissolving a starting PLG copolymer material, which is not a product of hydrolysis of a higher molecular weight PLG copolymer material, in a solvent, then precipitating the low-burst copolymer material with a non-solvent.
  • a PLG(p) copolymer can be a component of a constant release copolymer as disclosed and claimed herein.
  • PLG copolymer a type of low burst PLG copolymer, referred to herein as a "core diol" copolymer, as disclosed in patent application U.S. Ser. No. 11/469,392, is a PLG copolymer adapted for use in a controlled release formulation characterized by, for example, a structure as shown:
  • R a is an alkane diradical comprising about 4 to about 8 carbon atoms;
  • R b is hydrogen or methyl with the proviso that both R b groups are identical;
  • R c is hydrogen or methyl with the proviso that both R c groups are identical; each L/G independently comprises a lactide/glycolide copolymer segment; the polymer has substantially no titratable carboxylic acid groups, and the polymer has a weight average molecular weight of from about 6 kD to about 200 kD.
  • PLG copolymer Another type of low burst PLG copolymer, referred to herein as an "SFE- purified" PLG copolymer, as disclosed in the patent application filed herewith, is characterized as a PLG copolymer that has been purified by extraction with a supercritical fluid comprising carbon dioxide.
  • the PLG copolymer used in the inventive constant release copolymer composition can be of the PLGH type, i.e., having acidic carboxylic acid end groups on the molecular chains.
  • the PLGH copolymer can be either purified or unpurified. When a purified PLGH of the PLGH(p) type is used, that is, a PLGH that has been purified by solvent precipitation as described in patent application U.S. Ser. No.
  • the control formulation including 15% risperidone in copolymer PLGH(p) (a purified 80/20 PLGH, i.e., 80 mole% lactide, 20 mole % glycolide, and free carboxylic acid end groups) without any added PLG oligomer, in N-methylpyrrolidone (NMP) solution, exhibits a release profile (indicated by closed circles) with time points taken on the days indicated and the error bars representing plus or minus one standard error. As can be seen, for the first seven days after emplacement of the depot, the rate of release approximates the ideal rate without significant initial burst and without falling below the linear ideal. However, by day 14 the percentage of risperidone released is significantly below ideal.
  • the ideal rate shows a cumulative release of about 67% of total risperidone. Contrarily, the measured total cumulative release is only at about 52%, or 0.77 of ideal. By the end of the 28 day time period, the cumulative release is only about 58% of total risperidone, which is less than two thirds of the ideal cumulative release of 90%.
  • the two release profiles indicated by the open and closed triangles depict the risperidone release versus time from inventive constant release copolymer compositions when 4.5% of 100% PLA (open triangles) or when 4.5% of 65/35 PLG (closed triangles), each of about 7-8 kDa average molecular weight and without free carboxylic acid groups is combined with the PLG copolymer.
  • the added PLG oligomer replaces by weight the PLG copolymer.
  • the release profiles more closely approximate the ideal linear release profile, particularly during the time period near the end of release, at about 20-28 days.
  • the 100% PLA oligomer system provides a final release level of about 67% of total risperidone, and the 65/35 oligomer provides a final release level of about 82% of the total risperidone; both are substantially higher than in the system without added oligomer.
  • inventive copolymer controlled release formulations are within experimental error of the ideal at the 21 day time point, whereas the cumulative release of the formulation lacking the oligomer additives is only about 0.65 of the ideal. It is clearly seen that the addition of the oligomers substantially eliminates the late- term drop-off in the rate of release of the risperidone from this controlled release formulation.
  • the two curves indicated by open and closed squares signify compositions where the added PLG oligomer replaces solvent NMP; accordingly, the ratio of PLG oligomer to PLG copolymer is lower than in cases where the oligomer replaces by weight the copolymer, which may account for the greater deviation from ideality of these two compositions.
  • Figure 2 has the Day One release data from the same study with error bars of one standard error. This shows that the Day One release is comparable for all the formulations.
  • Figure 3 (experimental procedure in Example 4) shows data for the release of octreotide, a peptide analog of molecular weight slightly greater than 1000, in rats from a controlled release formulation adapted to release the drug over a period of 90 days.
  • the control formulation (closed circles) is composed of a purified PLGH copolymer, in this case 85/15 PLGH(p), without any added PLG oligomer.
  • the cumulative release curve deviates significantly from the ideal, which is a straight line between 0% at 0 days and about 90% at 90 days. After some initial burst between 0 and about 2 days, the control release profile reaches a maximum variance above the ideal release line at about 40 days, then tapers off to a lower release rate (lower slope of the line) late in the period, particularly between about 70-90 days.
  • the other four lines represent various inventive compositions comprising a PLG copolymer and a PLG oligomer.
  • the open squares and open triangles represent the release profiles of the octreotide from 85/15 PLGH(p) formulations including 4.5% PLA of about 7 kDa average molecular weight and lacking carboxylic acid end groups, wherein the total PLG copolymer concentrations in NMP are respectively 50% and 45%.
  • the closed black squares and closed triangles represent the release profiles of the octreotide from PLGH(p) copolymer formulations comprising 4.5% 65/35 PLG oligomers of less than 10 kDa molecular weight and lacking carboxylic end groups, wherein the total PLG copolymer concentrations in NMP are respectively 50% and 45%.
  • Figure 4 shows a 90-day release profile of octreotide in rats from a control and two inventive copolymer compositions, comparable to the study shown in Figure 3, except using an unpurified PLGH copolymer.
  • the use of the unpurified copolymer appears to overwhelm the modification of the release profile by addition of the oligomers.
  • Figure 5 shows Day One release data for GHRP-I from depots of controlled release formulations emplaced in rats.
  • the formulations include a control containing only a purified 75/25 PLGH and six test systems, each containing a copolymer system composed of the 75/25 PLGH(p) and a PLG oligomer, such as a PLA oligomer, 65/35 PLG oligomer or 65/35 PLGH oligomer.
  • the Day One releases for all of these formulations are comparable.
  • Figure 6 shows 28-day release profiles for GHRP-I from controlled release depots emplaced in rats for the same set of formulations as in Figure 5.
  • Figure 7 shows Day One release data for GHRP-I from depots of controlled release formulations emplaced in rats.
  • the formulations include a control containing only an unpurified 75/25 PLGH and six test systems, each containing a copolymer system of the unpurified PLGH and a PLG oligomer, such as a PLA oligomer, 65/35 PLG oligomer or 65/35 PLGH oligomer. This shows that the Day One release from all these formulations is comparable.
  • inventive copolymer composition is adapted to control non-linearity of release from controlled release formulation such as those of the Atrigel ® type, and, especially when used with a low burst PLG copolymer such as a PLGH(p), provides for substantially more linearity of release, a closer approach to zero-order release kinetics, than do art copolymer systems.
  • this copolymer system can be varied by the skilled artisan to adjust the properties of the copolymer system and of a controlled release formulation incorporating the system.
  • the relative proportion of the PLG oligomer in the constant release copolymer composition, and the molecular properties of the oligomer as well as of the PLG copolymer can be varied to achieve a particular desired result in terms of the release profile for a particular drug.
  • the molecular properties of the bioactive agents themselves vary depending upon the nature of the agent in question, for a given agent the parameters can be adjusted by the skilled artisan using routine experimentation to provide the desired release profile.
  • the hydrophobicity of the oligomer and of the PLG copolymer can be adjusted by altering the relative proportions of lactide and glycolide units.
  • the molecular weights of the PLG copolymer and, to a lesser extent, of the PLG oligomer, can be varied.
  • Typical molecular weights of the PLG copolymer can be between about
  • the weight average molecular weight can be about 10-50 kDa with a polydispersity index of about 1.4-2.0, having separated therefrom a copolymer fraction characterized by a weight average molecular weight of about 4-10 kDa and a polydispersity index of about 1.4 to 2.5.
  • the weight average molecular weight can be about 28-35 kDa with a polydispersity index of about 1.4-1.5.
  • the solvent used in the controlled release formulation can be changed, as can routinely be done by a person of ordinary skill in the art without undue experimentation, to adjust the controlled release properties of the formulation.
  • the solvent has at least a small degree of solubility in body fluids.
  • the solvent can be completely soluble in the body fluids.
  • the organic solvent can be N-methylpyrrolidone, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, polyethylene glycol 200, polyethylene glycol 300, or methoxypolyethylene glycol 350, or a mixture thereof.
  • inventive copolymer compositions can also be used with controlled release formulations other than of the Atrigel ® type, in which other solvents may be used.
  • embodiments of the constant release copolymer composition of the invention can be used with controlled release formulations including microparticles, nanoparticles, emulsions, solid monolithic implants, and the like.
  • concentrations of the drug and of the inventive PLG copolymer/oligomer composition in the solvent can be varied, and the amount of the formulation emplaced within the patient can also be adjusted.
  • biodegradable polyesters other than poly(lactide- glycolide), such as, for example, poly(caprolactone) and its copolymers can be components of a controlled release formulation also incorporating the inventive copolymer composition.
  • the controlled release formulation can be prepared by combining the PLG copolymer, the PLG oligomer, the bioactive agent, and the organic solvent.
  • the PLG copolymer and the oligomer can be premixed as solids, then dissolved in the solvent, followed by addition of the bioactive agent immediately prior to emplacement of the formulation in the patient.
  • the formulation can be sterilized by means known in the art, for example, gamma irradiation or by electron beam radiation.
  • a controlled release formulation can be made up by dissolving the inventive copolymer system in an organic solvent that is at least somewhat soluble in body fluids at a suitable concentration and adding a medically indicated bioactive agent.
  • Various embodiments of the invention further provide methods of administering a bioactive agent to a patient over a prolonged period of time, wherein a substantially constant rate of release of the bioactive agent is achieved, the method involving administering to the patient an embodiment of the inventive controlled release formulation of the bioactive agent.
  • the depot can be emplaced at any suitable position within the patient's body tissues, for example, subcutaneously adjacent to the abdominal wall, or within the abdominal cavity, within a muscle, within an eyeball, within a cerebral ventricle, or the like.
  • a depot of the Atrigel ® type is emplaced with a hypodermic syringe, but other devices or methods as are known in the art can be employed.
  • the bioactive agent contained within the controlled release formulation including an inventive copolymer system is adapted to treat the malcondition for which it is administered.
  • the agent can be leuprolide when the malcondition is prostate cancer; octreotide when the malcondition is acromegaly, risperidone when the malcondition is psychosis, an analgesic when the malcondition is pain, and so forth.
  • Formulations adapted to release the bioactive agent over various periods of time can be used as medically indicated.
  • a long term formulation such as a formulation adapted to release the bioactive agent leuprolide for a period of 6 months or more can be used.
  • a formulation can be used that is adapted to release the analgesic agent, for example a COX-2 inhibitor, for a shorter period, such as for 30 days.
  • All polymers and oligomers used in the examples were prepared by bulk copolymerization of DL lactide and glycolide using tin II 2-ethylhexanoate (stannous octoate) as the catalyst.
  • PLG oligomers were prepared using 1 ,6 hexanediol as the initiator and a reaction temperature of approximately 145°C.
  • the PLGH polymers and oligomer were prepared using glycolic acid as the initiator and a reaction temperature of approximately 165 °C.
  • the ratio of initiator to comonomers was varied to change the molecular weight of the polymer. The higher this ratio, the lower the molecular weight of the polymer. The reactions were run for approximately 2.5 hours.
  • Two samples of PLG oligomers were prepared as described: 100 mole % lactide, and 65 mole % lactide / 35 mole % glycolide, both using a hexane-1,6- diol core such that the product oligomers possessed terminal hydroxyl groups with substantially no free carboxylic acid groups.
  • the 100 mole% polylactide had an average molecular weight of 7 kDa
  • the 65/35 lactide-glycolide oligomer had an average molecular weight of 8 kDa.
  • One 65/35 PLGH oligomer with a molecular weight of 9 kDa was prepared as described.
  • Each retrieved implant was then analyzed by HPLC for the amount of active remaining in the implant. This was then subtracted from the amount of active present in the injection weight to determine the cumulative percent release.
  • a variety of delivery systems were prepared by mixing an 80/20 PLGH base polymer (purified or not purified) with N-methyl-pyrrolidone and optionally one of the PLG oligomers to form a solution.
  • the delivery systems are described in Table 1. These delivery systems were filled into syringe.
  • the delivery systems were gamma irradiated at 18 - 28 kGray either in bulk or in the syringe.
  • a second set of syringes was filled with risperidone powder.
  • the contents of a delivery system syringe and a risperidone syringe were mixed by coupling the syringes and passing the syringe contents back and forth to prepare a final formulation of 15 % (weight/weight) risperidone.
  • Table 1 Composition of various PLG copolymer / oligomer Delivery Systems tested with Risperidone in a 28 Day Study
  • Table 2 gives the cumulative percent release for the time points tested for an ideal linear release with 90% released on day 28.
  • Tables 3 through 8 give the percent release data for 15% risperidone mixed with delivery systems 1 through 6, respectively.
  • the tables include the mean value, standard deviation (SD) and standard error (SE) for each time point. Figure 1 shows these results graphically with error bars of plus or minus the standard error.
  • Table 9 Composition of various PLG copolymer / PLGH oligomer Delivery Systems tested with Risperidone in a One Day Study
  • Table 10 Day one percent release for formulations 7 and 8 (containing 65/35 PLGH oligomer)
  • ODP octreotide drug powder
  • Table 1 1 presents the delivery systems that were studied in which a 25 purified 85/15 PLGH is the base polymer. These octreotide formulations were then tested in rats as described in Example 2 with time points of 1 , 7, 14, 28, 42, 60, 76 and 90 days. Results are shown in Figure 3 with error bars of plus or minus one standard error.
  • Table 11 Composition of Purified PLG H/ oligomer Delivery Systems tested with Octreotide in a 90 Day Study
  • Table 12 presents the delivery systems that were studied in which an unpurified 85/15 PLGH is the base polymer. These octreotide formulations were then tested in rats as described in Example 2 with time points of 1 , 7, 14, 28, 42, 60, 76 and 90 days. Results are shown in Figure 4 with error bars of plus or minus one standard error.
  • Table 12 Composition of Unpurified PLGH/ oligomer Delivery Systems tested with Octreotide in a 90 Day Study
  • a variety of delivery systems were prepared by mixing a 75/25 PLGH base polymer (purified or not purified) (21 kDa) with N-methyl-pyrrolidone and optionally one of the PLG oligomers to form a solution.
  • the delivery systems are described in Tables 13 and 14. These delivery systems were filled into syringe.
  • the delivery systems were gamma irradiated at 18 - 28 kGray either in bulk or in the syringe.
  • a second set of syringes was prepared by lyophilization of an aqueous solution of GHRP-I acetate, citric acid and acetic acid.
  • the contents of a delivery system syringe and a GHRP-I syringe were mixed by coupling the syringes and passing the syringe contents back and forth to prepare a final formulation of 10 % (weight/weight) GHRP-I acetate, 1.1% (weight/weight) citric acid and 1.4% % (weight/weight) acetic acid.
  • Table 13 presents the delivery systems that were studied in which a purified 75/25 PLGH is the base polymer. These GHRP-I formulations were then tested in rats as described in Example 2 with time points of 1 , 3, 7, 14 and 28 days. Results are shown in Figures 5 and 6 with error bars of one standard error.
  • Figure 5 presents the day one release data.
  • Figure 6 presents the cumulative release minus day one release for the subsequent time points. This is to clarify the differences in release rate at these later time points.
  • Table 13 Composition of Purified PLG H/ oligomer Delivery Systems tested with GHRP-I in a 28 Day Study
  • Table 14 presents the delivery systems that were studied in which an unpurified 75/25 PLGH is the base polymer. These GHRP-I formulations were then tested in rats as described in Example 2 with time points of 1, 3, 7, 14 and 28 days. Results are shown in Figures 5 and 6 with error bars of one standard error.
  • Figure 7 presents the day one release data.
  • Figure 8 presents the cumulative release minus day one release for the subsequent time points. This is to clarify the differences in release rate at these later time points.
  • Table 14 Composition of Unpurified PLG H/ oligomer Delivery Systems tested with GHRP-I in a 28 Day Study
  • description of a release profile of about 20-28 days should be considered to have specifically disclosed subranges, such as 21 to 27 days, 22 to 26 days, 23 to 25 days, etc., as well as individual numbers within that range, such as 21 days, 23 days, 26 days, etc. This construction applies regardless of the breadth of the range or baseline threshold and in all contexts throughout this disclosure.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition copolymérique à libération continue destinée à être utilisée dans une préparation à libération contrôlée d'un agent bioactif, telle qu'une préparation conçue pour être implantée dans des tissus organiques d'un patient sous forme de dépôt afin de libérer l'agent au cours d'une période temporelle définie, le copolymère permettant une vitesse de libération pratiquement continue de l'agent bioactif au cours de la période pendant laquelle le dépôt réside dans les tissus organiques. Le copolymère consiste en un copolymère PLG et en un oligomère PLG présentant un poids moléculaire moyen est de 5-10 kDa environ et pouvant ne pas contenir de groupes acides carboxyliques libres. Quand le copolymère PLG est un copolymère à libération lente, la composition copolymérique à libération continue est une composition à libération continue et lente conçue pour être implantée dans les tissus organiques d'un mammifère où l'agent bioactif se libère à une vitesse pratiquement continue.
EP09758744A 2008-06-03 2009-06-03 Formulation copolymérique à libération contrôlée présentant une cinétique de libération améliorée Withdrawn EP2309982A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5847708P 2008-06-03 2008-06-03
PCT/US2009/003362 WO2009148580A2 (fr) 2008-06-03 2009-06-03 Formulation copolymérique à libération contrôlée présentant une cinétique de libération améliorée

Publications (1)

Publication Number Publication Date
EP2309982A2 true EP2309982A2 (fr) 2011-04-20

Family

ID=41110676

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09758744A Withdrawn EP2309982A2 (fr) 2008-06-03 2009-06-03 Formulation copolymérique à libération contrôlée présentant une cinétique de libération améliorée

Country Status (6)

Country Link
US (1) US8877225B2 (fr)
EP (1) EP2309982A2 (fr)
CN (1) CN102112107A (fr)
AU (1) AU2009255675B2 (fr)
CA (1) CA2726763A1 (fr)
WO (1) WO2009148580A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470359B2 (en) * 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
MX2008009125A (es) 2006-01-18 2008-10-23 Qps Llc Composiciones farmaceuticas con estabilidad mejorada.
MX337286B (es) 2007-05-25 2016-02-22 Indivior Uk Ltd Formulaciones de transferencia sostenida de compuestos de risperidona.
WO2009148580A2 (fr) 2008-06-03 2009-12-10 Qlt Usa, Inc. Formulation copolymérique à libération contrôlée présentant une cinétique de libération améliorée
EA033537B1 (ru) 2013-03-11 2019-10-31 Durect Corp Инъекционная композиция с контролируемым высвобождением, содержащая жидкий носитель с высокой вязкостью
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
JP2018527397A (ja) 2015-09-21 2018-09-20 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 徐放性オランザピン製剤
WO2018172850A1 (fr) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Formulations d'olanzapine à libération prolongée
AU2018345844B2 (en) 2017-10-06 2024-03-07 Foundry Therapeutics, Inc. Implantable depots for the controlled release of therapeutic agents
EP4277661A1 (fr) 2021-01-18 2023-11-22 Anton Frenkel Forme posologique pharmaceutique
WO2023281406A1 (fr) 2021-07-06 2023-01-12 Mark Hasleton Traitement du syndrome de sevrage aux inhibiteurs de recapture de la sérotonine

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) * 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5487897A (en) * 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
USRE37950E1 (en) * 1990-04-24 2002-12-31 Atrix Laboratories Biogradable in-situ forming implants and methods of producing the same
AU2605592A (en) * 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
EP0560014A1 (fr) * 1992-03-12 1993-09-15 Atrix Laboratories, Inc. Pansement sous forme de film biodégradable et méthode pour sa fabrication
US5681873A (en) * 1993-10-14 1997-10-28 Atrix Laboratories, Inc. Biodegradable polymeric composition
ATE209907T1 (de) * 1994-04-08 2001-12-15 Atrix Lab Inc Flüssige mittel zur wirkstoffabgabe
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6261583B1 (en) * 1998-07-28 2001-07-17 Atrix Laboratories, Inc. Moldable solid delivery system
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6355657B1 (en) * 1998-12-30 2002-03-12 Atrix Laboratories, Inc. System for percutaneous delivery of opioid analgesics
US6461631B1 (en) * 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
KR100772950B1 (ko) 2000-08-07 2007-11-02 와꼬 쥰야꾸 고교 가부시키가이샤 젖산 중합체 및 이의 제조 방법
US6433129B1 (en) * 2000-11-08 2002-08-13 Millennium Cell, Inc. Compositions and processes for synthesizing borohydride compounds
US8470359B2 (en) * 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
WO2002038185A2 (fr) 2000-11-13 2002-05-16 Atrix Laboratories, Inc. Systeme d'administration injectable a liberation prolongee comprenant du loperamide
US20030049320A1 (en) * 2000-12-18 2003-03-13 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20090092650A1 (en) 2004-12-15 2009-04-09 Warren Stephen L Sustained Delivery Formulations of Octreotide Compounds
PT2079767E (pt) * 2006-10-11 2014-10-07 Tolmar Therapeutics Inc Preparação de poliésteres biodegradáveis com propriedades de baixa rotura por extração com fluido supercrítico
PL2115029T3 (pl) * 2007-02-15 2016-01-29 Tolmar Therapeutics Inc Poli(laktyd/glikolid) o niskim efekcie nagłego uwalniania i sposoby wytwarzania polimerów
WO2009148580A2 (fr) 2008-06-03 2009-12-10 Qlt Usa, Inc. Formulation copolymérique à libération contrôlée présentant une cinétique de libération améliorée

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009148580A2 *

Also Published As

Publication number Publication date
CN102112107A (zh) 2011-06-29
AU2009255675A1 (en) 2009-12-10
WO2009148580A3 (fr) 2010-11-25
US20090325879A1 (en) 2009-12-31
US8877225B2 (en) 2014-11-04
CA2726763A1 (fr) 2009-12-10
AU2009255675B2 (en) 2014-10-09
WO2009148580A2 (fr) 2009-12-10

Similar Documents

Publication Publication Date Title
AU2009255675B2 (en) Controlled release copolymer formulation with improved release kinetics
US11717572B2 (en) Low-burst polymers and methods to produce polymer
US10047193B2 (en) Sustained release polymer
EP2106787B1 (fr) Compositions copolymères de bloc biodégradable pour l'administration de médicaments
KR20070059101A (ko) 가역성 열적 겔화 특성을 나타내는 생물분해성 이중블록공중합체 및 이의 사용 방법

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20101220

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20131112

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170103